This one-day symposium will provide a platform for some of the leading names in the field of epigenetics to present their research on the underpinning biology and the discovery of novel therapeutic targets to the development of chemical probes and small molecule inhibitors.
The day will comprise of a series of lectures from internationally leading scientists from both academia and industry, and a poster session for discussion and networking. The meeting will provide early stage career researchers with a fundamental understanding of epigenetics and how it relates to the frontiers of drug discovery.
The meeting is aimed at scientists in the industrial and academic fields with a background in epigenetic chemical biology or drug discovery. It is ideally suited to those studying for a postgraduate degree or working in the pharmaceutical or biotechnology industry.
Programme
- Eli Lilly, Windlesham, UK
- Thursday 7 September 2017
- Organised by SCI's Young Chemists' Panel
The day will comprise of a series of lectures from internationally leading scientists from both academia and industry, and a poster session for discussion and networking. The meeting will provide early stage career researchers with a fundamental understanding of epigenetics and how it relates to the frontiers of drug discovery.
The meeting is aimed at scientists in the industrial and academic fields with a background in epigenetic chemical biology or drug discovery. It is ideally suited to those studying for a postgraduate degree or working in the pharmaceutical or biotechnology industry.
Programme
- 10.20 Opening remarks
- 10.30 Plenary talk: Discovery of Selective Inhibitors for Protein Metltransferases - Professor Jian Jin, Icahn School of Medicine (Mount Sinai)
- 11.15 Non-BET bromodomains - Dr Phil Humphreys, GlaxoSmithKline
- 11.45 Flash Presentations from abstracts (4 x 5 min talks)
- 12.15 Lunch, posters and exhibition
- 13.30 Small Molecule Designer Libraries targeting HDACs and Bromodomains - Professor John Spencer, University of Sussex
- 14.00 Bump-and-hole and PROTACs - Professor Alessio Ciulli, University of Dundee
- 14.30 Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models - Dr Jon Winter-Holt, Astra Zeneca
- 15.00 Refreshment break, posters and exhibition
- 15.30 Title TBC - Dr Oleg Fedorov, Structural Genomics Consortium
- 16.00 Plenary talk: Jmj enzymes - more than lysine demethylases - Professor Chris Schofield FRS, University of Oxford
- 16.45 Closing remarks & poster prizes
